The online version of this article (doi:10.1186/1752-1947-8-6) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
BCC followed up and managed the patient and drafted the manuscript. VQG drafted the manuscript. CLR managed and controlled drugs. MIPM performed surgery. LCR and NPA managed the patient. SVM and AMM diagnosed the patient. CRC treated and followed up the skin toxicity. MMV drafted the manuscript. All authors read and approved the final manuscript.
Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences between paclitaxel and other drugs.
We describe the case of a 55-year-old Caucasian woman with locally advanced breast cancer treated with neoadjuvant therapy who developed secondary skin toxicity due to delayed hypersensitivity to taxanes. She received Adriamycin® (doxorubicin), cyclophosphamide and docetaxel and developed toxicity that promoted treatment delay and a switch to weekly paclitaxel. After the third and fourth weeks of treatment, paclitaxel toxicities also induced treatment delay and paclitaxel was switched to nanoparticle albumin-bound paclitaxel. She completed the five planned nanoparticle albumin-bound paclitaxel cycles with acceptable tolerability (including persistent grade 2 neuropathy) and without dose delay or adjustments. Clinical response was achieved although pathological response was not good.
Nanoparticle albumin-bound paclitaxel treatment is a good option for patients with breast cancer with taxanes-related skin toxicity. This drug allows the treatment to be completed with acceptable tolerance in our case.
Vishnu P, Roy V: Nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Womens Health (Lond Engl). 2010, 6 (4): 495-506. 10.2217/whe.10.42. CrossRef
Vishnu P, Roy V: Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer. Breast Cancer (Auckl). 2011, 5: 53-65.
Shapiro J, Richardson GE: Paclitaxel-induced “recall” soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol. 1994, 12 (10): 2237-2238. PubMed
Hryniuk W, Frei E, Wright FA: A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol. 1998, 16 (9): 3137-3147. PubMed
Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan cancer institute. J Clin Oncol. 1998, 16 (1): 93-100. PubMed
Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P: Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009, 27 (22): 3611-3619. 10.1200/JCO.2008.18.5397. CrossRefPubMed
- Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
Beatriz Cirauqui Cirauqui
Vanesa Quiroga García
Clara Lezcano Rubio
Maria Iciar Pascual Miguel
Laia Capdevila Riera
Nuria Pardo Aranda
Sara Vizcaya Martín
Antonio Mariscal Martínez
Clara Rodríguez Caruncho
Mireia Margelí Vila
- BioMed Central